Buys
Open market- Shares
- Avg price
- Total value
Alastair Garfield - Chief Scientific Officer at RHYTHM PHARMACEUTICALS, INC.
Issuer-level insider activity
- Role
- Chief Scientific Officer
- Issuer ticker
- RYTM on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
Past-year transaction volume for Alastair Garfield in RHYTHM PHARMACEUTICALS, INC.
Sells
Open market- Shares
- -7,763
- Avg price
- $117.57
- Total value
- -$912,703
Net
Past year- Shares
- -7,763
- Share %
- -100%
- Total value
- -$912,703
Reported holdings for Alastair Garfield in RHYTHM PHARMACEUTICALS, INC.
Form 4 holding
Chief Scientific Officer
RHYTHM PHARMACEUTICALS, INC.
- Security class
- Restricted Stock Units
- Shares / value
- 8,888
- Estimated value
- $1,524,913
- Report date
- 01 Jul 2026
- Price
- $57.22
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Chief Scientific Officer
RHYTHM PHARMACEUTICALS, INC.
- Security class
- Common Stock
- Shares / value
- 2,295
- Estimated value
- $273,492
- Report date
- 13 Aug 2026
- Price
- $119.17
- Ownership
- Direct
Form 4 holding
Chief Scientific Officer
RHYTHM PHARMACEUTICALS, INC.
- Security class
- Stock Options (Right to Buy)
- Shares / value
- 25,000
- Estimated value
- Report date
- 11 Feb 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Alastair Garfield in RHYTHM PHARMACEUTICALS, INC.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.